Female sex at birth, age of 65 years or older, and 32 specific medications were identified as factors for drug-related candidiasis.

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

US FDA grants orphan drug designation to Zenith Epigenetics’ ZEN-3694 to treat NUT carcinoma: Calgary, Alberta Tuesday, October 28, 2025, 17:00 Hrs [IST] Zenith Epigenetics Ltd.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics Li ...

(A) The Incucyte® Apoptosis Assay allows automated imaging and quantitative analysis of every well of a 96/384-well plate, ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Prior research on the potential role of cytokines found that IL-6 signaling can reprogram and alter T-cell immune responses ...

Orphan Drug Designation The purpose of the Orphan Product program is to support the development and evaluation of new treatments for rare diseases. FDA grants Orphan Drug designation to ...